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Gemcitabine (20,20-difluorodeoxycytidine) is a deoxycytidine analogue that is activated by deoxycytidine kinase (dCK) to its
monophosphate and subsequently to its triphosphate dFdCTP, which is incorporated into both RNA and DNA, leading to DNA
damage. Multidrug resistance (MDR) is characterised by an overexpression of the membrane efflux pumps P-glycoprotein (P-gP) or
multidrug resistance-associated protein (MRP). Gemcitabine was tested against human melanoma, non-small-cell lung cancer, small-
cell lung cancer, epidermoid carcinoma and ovarian cancer cells with an MDR phenotype as a result of selection by drug exposure or
by transfection with the mdr1 gene. These cell lines were nine- to 72-fold more sensitive to gemcitabine than their parental cell lines.
The doxorubicin-resistant cells 2R120 (MRP1) and 2R160 (P-gP) were nine- and 28-fold more sensitive to gemcitabine than their
parental SW1573 cells, respectively (Po0.01), which was completely reverted by 25mM verapamil. In 2R120 and 2R160 cells, dCK
activities were seven- and four-fold higher than in SW1573, respectively, which was associated with an increased dCK mRNA and
dCK protein. Inactivation by deoxycytidine deaminase was 2.9- and 2.2-fold decreased in 2R120 and 2R160, respectively. dFdCTP
accumulation was similar in SW1573 and its MDR variants after 24h exposure to 0.1mM gemcitabine, but dFdCTP was retained
longer in 2R120 (Po0.001) and 2R160 (Po0.003) cells. 2R120 and 2R160 cells also incorporated four- and six-fold more
[
3H]gemcitabine into DNA (Po0.05), respectively. P-glycoprotein and MRP1 overexpression possibly caused a cellular stress
resulting in increased gemcitabine metabolism and sensitivity, while reversal of collateral gemcitabine sensitivity by verapamil also
suggests a direct relation between the presence of membrane efflux pumps and gemcitabine sensitivity.
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Gemcitabine (20,20-difluorodeoxycytidine) is a deoxycytidine
analogue with proven activity in ovarian, pancreatic and non-
small cell lung cancer (NSCLC) in vivo, in vitro and in the clinic
(Abratt et al, 1994; Lund et al, 1994; Braakhuis et al, 1995;
Heinemann, 2001). Deoxycytidine kinase (dCK) phosphorylates
both deoxycytidine (dCyd) and gemcitabine to their monopho-
sphates, which are subsequently phosphorylated to deoxycytidine
triphosphate (dCTP) and gemcitabine triphosphate (dFdCTP),
respectively. Gemcitabine can be inactivated by deamination
catalysed by deoxycytidine deaminase (dCDA) (Heinemann et al,
1988). dFdCTP can be incorporated into both DNA and RNA
(Huang et al, 1991; Ruiz van Haperen et al, 1993b). The
mitochondrial enzyme thymidine kinase 2 (TK2) phosphorylates
the natural nucleosides thymidine and deoxycytidine, but also
gemcitabine, although, to a lesser extent than dCK (Eriksson et al,
1991; Bergman et al, 1999). This is in contrast to the cytosolic
enzyme thymidine kinase 1, which does not phosphorylate
deoxycytidine (Eriksson et al, 1991). Since dCTP is the major
natural feedback inhibitor of dCK and competes with dFdCTP for
DNA polymerase, an increase in dCTP pools will decrease
gemcitabine sensitivity (Heinemann et al, 1990; Ruiz van Haperen
and Peters, 1994).
Crossresistance to some structurally and functionally unrelated
natural-derived drugs (e.g. daunomycin, etoposide, vincristine) is
called multidrug resistance (MDR). Multidrug resistance is caused
by overexpression of the plasma membrane drug efflux pumps P-
glycoprotein (P-gP), the product of the mdr1 gene, and multidrug
resistance-associated protein (MRP) (Endicott and Ling, 1989;
Grant et al, 1994). These pumps can be blocked by verapamil
(Cornwell et al, 1987). The MRP family currently has seven
members, all with different drug specificities (Borst et al, 2000).
Although gemcitabine is a substrate for MRP5 efflux pump
(Davidson et al, 2002), it is predominantly transported into the
cell across cell membranes via facilitated diffusion (equilibrative
nucleoside transporter, ENT) and sodium-dependent concentra-
tive mechanisms (concentrative nucleoside transporter, CNT)
(Mackey et al, 1998, 1999; Ritzel et al, 2001). Jensen et al (1997)
observed that some small-cell lung cancer (SCLC) cells with P-gP
overexpression were more sensitive to gemcitabine and the
structurally related deoxycytidine analogue 1-b-D-arabinofurano-
sylcytidine (cytarabine, ara-C), although Grant et al (1995)
observed crossresistance to ara-C in a P-gP-overexpressing
leukaemia cell line.
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sWe tested the sensitivities to gemcitabine of various pairs of cell
lines and their MDR variants derived from different human
tumours. The human NSCLC cell line SW1573 and its P-gP- and
MRP1-overexpressing variants were used for mechanistic studies
on gemcitabine sensitivity of MDR cells. Moreover, a possible role
of the membrane efflux pumps in gemcitabine sensitivity was
investigated.
MATERIALS AND METHODS
Chemicals and reagents
Dulbecco’s modified eagle’s medium (DMEM) and Rosswell Park
Memorial Institute (RPMI) medium were purchased from Flow
Laboratories (Irvine, UK); foetal calf serum from Life Technologies
(New York, NY, USA); trichloroacetic acid (TCA), glutamine and
gentamicin from Merck (Darmstadt, Germany); trypsin and
sulphorhodamine B (SRB) from Sigma Chemical Co. (St Louis,
USA); and VP-16 (etoposide) from Bristol-Myers Squibb (Weesp,
the Netherlands). Eli Lilly (Indianapolis, IN, USA) kindly sup-
plied gemcitabine and [5-
3H]gemcitabine (16.7Cimmol
 1).
[5-
3H]Deoxycytidine was purchased from Moravek (Brea, CA,
USA) [2-
14C]thymidine (58.8Cimmol
 1) was from Dupont de
Nemours NEND (Dreiech, Germany) and [5-
3H]uridine
(27.8Cimmol
 1) from Amersham International (Buckingham-
shire, England). All other chemicals were of analytical grade and
commercially available.
Cell culture
The in vitro experiments were performed with five parental cell
lines and eight MDR variants (Table 1). All cell lines were grown in
monolayers in DMEM, except for GLC4S and GLC4/ADR, which
grew as semimultilayers in RPMI, at 371C and 5% CO2. These cells
grow in several layers, but are only loosely attached to the flask.
Both media were supplemented with 7.5% heat-inactivated foetal
calf serum, and 250ngml
 1 gentamicin. Cells were regularly
screened for Mycoplasma contamination by using a rapid
detection system with a
3H-labelled DNA probe (Gen-Probe, San
Diego, CA, USA) and were found to be negative.
Chemosensitivity testing
The determination of the IC50 (the drug concentration causing
50% growth inhibition) in monolayer cell lines was performed
using the SRB assay. The assay was performed using the NCI
protocol with some small modifications (Skehan et al, 1990;
Keepers et al, 1991). For GLC4S and GLC4/ADR, both growing as
semimultilayers, the tetrazolium (MTT) assay was performed as
previously described (Keepers et al, 1991). Culture conditions were
optimised for all cell lines. For both assays, the cells were plated in
96-well plates at day 1, in different densities, depending on their
doubling times (4000–15000 cells per well). The optimal plating
number was the highest number of cells, which enabled log-linear
growth for 4 days. Log-linear growth or exponential growth is the
phase of growth in which each descendant of the parental cell will
divide as well.
On day 2, cells were exposed to gemcitabine (final concentra-
tions ranged from 5 10
 16 to 5 10
 5 M), with or without 25mM
verapamil for 72h and optical density (OD) was estimated either
by the SRB or MTT assay and set at 100%; the OD of cells at the
day of drug administration was set at 0%. The IC50 was the drug
concentration resulting in a relative OD of 50%, total growth
inhibition when OD was similar to the initial value, 0%, and an OD
lower than the initial value 0% represents cell kill (Peters et al,
1993).
dCK enzyme activity
For determination of dCK activities, 10000g supernatants
were prepared with cold dCK buffer, containing 0.3 M Tris-HCl
(pH 8.0), essentially as described (Ruiz van Haperen et al, 1993a).
Protein content was estimated with the Biorad protein assay. To
25ml of supernatant containing 0.2–4.0 10
5 cells, 25mlo fa
substrate mixture was added (final concentrations: 10mM ATP,
5m M MgCl2,3 0 m M Tris-HCl and 230mM
3H-dCyd (final specific
activity 0.04Cimmol
 1)), with or without 1mM thymidine to
inhibit TK2-mediated phosphorylation of dCyd (Eriksson et al,
1991), and incubated at 371C for 15min. The radio-labelled
product dCMP was quantitated in a liquid scintillation counter,
after thin layer chromatography on polyethyleneimine cellulose
layers.
Table 1 MDR phenotype, sensitivity to gemcitabine and sensitivity factors of human cancer cell lines
Cell line Origin MDR phenotype
Doubling
time (h)
IC50 (nM)
gemcitabine
Sensitivity
factor
SW1573 NSCLC Parental 3575 17.0721
2R120
a DOX resistant, MRP1 5076 1.971.2 8.9***
2R160
a DOX resistant, P-gP 5076 0.670.4 27.9***
SW1573/S1(1.1)
b, c P-gP transfected 3072 5.772.4 3.0**
SW1573/S1(MRP)
b, c MRP1 transfected 3578 0.0570.02 340***
GLC4 SCLC Parental 2275 4.170.6 1
GLC4/ADR
b DOX resistant, MRP1 3179 0.470.2 11*
A2780 Ovarian Parental 2279 1.670.3 1
2780AD
d DOX resistant, P-gP 2678 0.0370.03 55**
KB3-1 Epidermoid Parental 16735 9 724 1
KB8-5
e Colchicine resistant, P-gP 1975 33.0720. 1.8 NS
BRO Melanoma Parental 2173 300787 1
BROmdr
f P-gP transfected 29743 3 712 9.0**
MDR¼multidrug resistance; NSCLC¼non-small-cell lung cancer; SCLC¼small-cell lung cancer; DOX¼doxorubicin; P-
gP¼P-glycoprotein; MRP¼multidrug resistance-associated protein. Cells were exposed to gemcitabine for 72h. Values
represent the mean IC507s.d. of at least three experiments. IC50¼50% growth-inhibiting concentration, sensitivity factor;
IC50 parental/IC50 MDR variant. Statistical analysis by t-test (independent samples); NS¼not significant, *Po0.05,
**Po0.01, ***Po0.001. References:
aKuiper et al (1990).
bZaman et al (1993).
cZaman et al (1994).
dLouie et al (1986).
eShen et al (1986).
fLincke et al (1990).
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sdCDA enzyme activity
Activity of dCDA was determined as described earlier (Ruiz van
Haperen et al, 1993a). Briefly, 10000g supernatants were prepared
and enzyme assays were performed at 371Ci n1–5 10
6 cells with
500mM dCyd as a substrate for 15 or 25min. The deaminated
product deoxyuridine was analysed using reversed phase high-
performance liquid chromatography (HPLC) (Ruiz van Haperen
et al, 1993a).
Quantitative reverse transcriptase–polymerase chain
reaction assay for dCK-mRNA with competitive templates
RNA was extracted from confluent growing cells using the
RNAzole method and cDNA samples were prepared as previously
described (Rots et al, 2000). Competitive template reverse
transcriptase–polymerase chain reaction (RT–PCR) assays for
dCK mRNA and the housekeeping gene b-actin were performed as
described previously (Kroep et al, 2002). Levels of expression were
reported as units of dCK-mRNA/10
6 b-actin mRNA molecules.
Western blot for dCK
Western blotting by affinity-purified rabbit antibody against
human dCK was performed as previously described (Hatzis et al,
1998).
dFdCTP accumulation and retention
For dFdCTP accumulation and retention, cells were plated in six-
well plates at 0.5–1.0 10
6 cells per well in 2ml medium, and
exposed to 0.1 or 1.0mM gemcitabine for 24h. For the retention,
cells were cultured in drug-free medium for 4 or 24h after
incubation. After harvesting, nucleotides were extracted and
quantitated with HPLC as previously described (Ruiz van Haperen
et al, 1994).
[
3H]Gemcitabine incorporation into DNA and RNA
Incorporation studies were performed using 96-well filter plates
essentially as described previously (Van der Wilt et al, 1993; Van
Moorsel et al, 1999a). A total of 1.0 10
5 cells per well were plated
in a volume of 100ml, whereafter 100mlo f[
3H]gemcitabine
containing medium (4Cimmol
 1) was added resulting in final
concentrations of 0.1 or 1.0mM. After 24h incubation, the medium
was removed by suction through the filters. Filters were washed
with TCA and phosphate-buffered saline (PBS), followed by
incubation with RNAse A or without RNAse A at 37
oC. After
termination of the reaction, the filters were washed again with
TCA, H2O and 70% ethanol, removed and radioactivity was
counted as described previously (Van Moorsel et al, 1999a).
Counts in wells incubated with RNAse A were considered to
represent [
3H]gemcitabine incorporated into DNA, the difference
in counts between incubation with or without RNAse A was
considered to represent [
3H]gemcitabine incorporation into RNA.
To correct for DNA and RNA synthesis, experiments were
performed simultaneously with cells exposed to 0.1 or 1.0mM cold
gemcitabine and 5.6mM [
14C]thymidine (62.8mCimmol
 1)o r
0.165mM [
3H]uridine (25Cimmol
 1). Cell numbers were estimated
by performing this experiment with cells exposed to unlabelled
gemcitabine in a concentration of 0.1 or 1.0mM (Van Moorsel et al,
1999a).
Fluorometric analysis of DNA unwinding assay
To measure the gemcitabine-induced DNA damage, the fluoro-
metric analysis of DNA unwinding (FADU) assay was used
(Birnboim and Jevcak, 1981; Bergman et al, 1996). Essentially,
3 10
6 cells were incubated for 24h at 371C with gemcitabine in a
concentration of 0.1 or 1.0mM. Cells exposed to 50mM VP-16 for
24h were used as a positive control, since this drug is known to
introduce double-strand (ds) DNA breaks very effectively, and
cells not exposed to drugs were used as a negative control. Cells
were lysed and exposed to an alkaline environment, allowing the
DNA to unwind. The extent of strand breaks in the DNA
determines the extent of DNA unwinding at the end of incubation.
The dsDNA was stained by ethidium bromide and the ratio of
fluorescence between treated and control samples was used to
determine the percentage dsDNA (Bergman et al, 1996).
Statistical analysis
In case of significant differences between parental and MDR cells, a
t-test was used to compare unpaired data of the two cell lines. The
computer program SPSS (version 7.5, SPSS, Inc., Chicago, IL, USA)
was used for statistical analysis.
RESULTS
Growth inhibition tests
The parental cell lines showed large differences in sensitivity to
gemcitabine, which was not related to their doubling time, this
indicates that differences in metabolic activation and mechanisms
of action are predominantly responsible for sensitivity to
gemcitabine. As a control, clonogenic assays were performed for
some cell lines as described previously (Bergman et al, 2000),
which also showed a similar difference in sensitivity (data not
shown). SW1573 cells were intermediately sensitive to gemcitabine
compared to the other parental cells; BRO, GLC4, KB3-1 and A2780
cells. All SW1573 variants were significantly (Po0.01) more
sensitive to gemcitabine than the parent (Figure 1, Table 1). 2R120
and 2R160 cells, the MRP1- and P-gP-overexpressing variants of
SW1573, respectively, were nine- and 28-fold more sensitive to
gemcitabine, respectively. The P-gP-transfected variant S1(1.1) was
three-fold more sensitive, but the largest difference was found for
the MRP1-transfected S1(MRP) cells, which were 340-fold more
sensitive to gemcitabine than SW1573 cells (Po0.001). The
doxorubicin-selected, MRP1-overexpressing variant of GLC4,
GLC4/ADR, was 11.1-fold more sensitive to gemcitabine than its
parental cells (Po0.05). The human ovarian cancer A2780 cells
were the most sensitive parental cells, but the doxorubicin-
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Figure 1 Representative growth inhibition curves of the human
melanoma cell line BRO (-m-) and its transfected variant BROmdr (-n-)
(broken line) and the human ovarian carcinoma cell line A2780 (-K-) and
its doxorubicin-resistant, P-gP-overexpressing variant A2780AD (-J-)
(solid line). Cells were exposed to gemcitabine for 72h.
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sresistant P-gP-overexpressing variant 2780AD was even more
sensitive to gemcitabine (Po0.01). KB8-5 cells were included since
P-gP was induced by exposure to colchicine; also this phenotype
was associated with increased sensitivity to gemcitabine. BRO cells
were the least sensitive of the parental cells tested, but its mdr1-
transfected variant was significantly more sensitive (Po0.01).
The MDR phenotype of doxorubicin resistance can be reversed
by the calcium-channel blocker verapamil. This phenomenon has
been used as a characteristic of the efflux pump. In order to
determine whether the activity of the pump was associated with the
collateral sensitivity to gemcitabine, we exposed SW1573 and its
variants to gemcitabine and verapamil. Verapamil almost com-
pletely reversed the gemcitabine sensitivity to the level of the
parental SW1573 cells (Figure 2). This reversal was significant in
2R160 and S1(MRP) cells (Po0.05).
Deoxycytidine kinase, thymidine kinase 2 and
deoxycytidine deaminase assays
Since gemcitabine cytotoxicity is dependent on its phosphoryla-
tion, we determined the activities of the enzymes involved in this
process. SW1573 cells had the lowest dCK activity, this activity was
6.6- and 4.0-fold higher in 2R120 (Po0.001) and 2R160 cells (not
significant), respectively (Table 2). In 2R120 cells, TK2 activity was
unchanged compared to its parental SW1573 cells. However, TK2
activity was two-fold lower in 2R160 than in SW1573 cells (not
significant).
The amount of dCK protein present in the cell as determined
with Western blots, revealed a 7.2- and 2.2-fold higher expression
in 2R120 and 2R160 cells, respectively, than in the parental
SW1573 cells (Table 2). In order to determine whether the increase
in dCK protein was the result of increased expression, we
determined the expression of dCK-mRNA (Table 2). The dCK/b-
actin ratio was 6.1- and 5.5-fold higher in 2R120 and 2R160 cells
than in the parental SW1573 cells, respectively (Po0.001).
dCDA activity was decreased 2.9- and 2.2-fold in 2R120 and
2R160 cells, respectively (Table 2).
dFdCTP accumulation and retention
The active metabolite of gemcitabine is dFdCTP. Besides its
accumulation, retention is also important for the cytotoxicity of
gemcitabine. No significant difference in dFdCTP accumulation
was found between the cell lines, both at 0.1 and 1.0mM
gemcitabine (Figure 3). In all cells, accumulation was concentra-
tion dependent, six- to eight-fold more dFdCTP accumulated at
1.0mM than at 0.1mM gemcitabine. At 0.1mM gemcitabine, dFdCTP
was retained longer in 2R120 (P¼0.001) and 2R160 (P¼0.003)
cells than in the parental cell line SW1573. At 1.0mM gemcitabine,
no difference in retention of dFdCTP was found between the cell
lines. Another active metabolite of gemcitabine, gemcitabine-
diphosphate was not detectable.
Gemcitabine incorporation into DNA and RNA, and DNA
damage
Following its accumulation, dFdCTP may be incorporated into
DNA and RNA. The extent and retention are dependent on DNA
and RNA polymerases, but also on subsequent excision. We not
only determined the total extent of incorporation but also its
relation to synthesis of DNA and RNA, which are inhibited by
gemcitabine. SW1573, 2R120 and 2R160 cells not exposed to
gemcitabine incorporated 53729, 8.775.0 and 4179pmol
2R120
2R160
S1(1.1)
S1(MRP)
0.1 1 10 100 1000
∗
∗
Sensitivity factor
Figure 2 Sensitivity factors to gemcitabine, without 25mM verapamil
(’) or with 25mM verapamil ( ) (IC50 of the MDR variants relative to IC50
of SW1573 was set at 1), of the MRP1-overexpressing 2R120, the P-gP-
overexpressing 2R160, the mdr1-transfected S1(1.1) and the MRP1-
transfected S1(MRP). Verapamil itself did not affect cellular growth. Values
are means7s.d. of at least three experiments. *Sensitivity with 25mM
verapamil statistically significantly different from gemcitabine alone (t-test,
independent samples, Po0.05).
Table 2 dCK, TK2 and dCDA activities and dCK protein and mRNA
expression in the human NSCLC cell line SW1573 and its doxorubicin
MDR variants; 2R120 (MRP1) and 2R160 (P-gP)
Enzyme SW1573 2R120 2R160
dCK Activity 0.370.08 2.170.3*** 1.370.7 NS
Protein 0.3 2.0 0.6
mRNA 0.5 3.1 2.8
TK2 0.270.2 0.270.3 0.170.2 NS
dCDA 3773.0 1373*** 1771***
Enzyme activities are means7s.d. of at least three experiments in nmolh
 1 per 10
6
cells. For dCK and TK2 activity, dCyd was used as a substrate with or without
thymidine to block TK2 activity. The difference in dCMP formation between dCyd as
a substrate and dCyd and thymidine as a substrate was considered as TK2 activity.
The protein content of SW1573, 2R120 and 2R160 cells was about 273777,
4427152 and 21078mg per 10
6 cells, respectively (means7s.d.). Protein and
mRNA expression are means of two and three separate experiments in (ODmm
 2)
and (dCK/b-actin  10
 3), respectively. Statistically different from SW1573 by t-test
(independent samples); NS¼not significant, ***Po0.001.
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Figure 3 Accumulation (&), of dFdCTP after 24h exposure to 0.1 or
1.0mM gemcitabine and its retention after suspension in drug-free medium
for 4h (’)o r2 4 h( ) in the human NSCLC cell line SW1573 and its
doxorubicin-resistant MDR cell lines; MRP1-overexpressing 2R120 and P-
gP-overexpressing 2R160. Values are means7s.d. of at least three
experiments. *Statistically significant different from SW1573 cells (t-test,
independent samples, Po0.005). n.d.¼not detectable.
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sthymidineh
 1 per 10
6 cells into DNA and 2.570.7, 2.772.9 and
3.170.5pmol uridineh
 1 per 10
6 cells into RNA, respectively. At
0.1mM gemcitabine, inhibition of DNA synthesis varied between 79
and 91%, and at 1mM gemcitabine between 94 and 97%. For
inhibition of RNA synthesis, these values were less pronounced
and varied between 0 and 4.7%, and 4.6 and 14.5%, respectively,
for the three cell lines.
When corrected for the inhibition of DNA synthesis, [
3H]gem-
citabine incorporation into DNA was greater at the higher
concentrations in all three cell lines, suggesting that incorporation
was concentration dependent (Figure 4). At 0.1mM gemcitabine
2R120 and 2R160 cells incorporated 9.6- (P¼0.04) and 2.8-fold
and at 1.0mM gemcitabine 7.1- (P¼0.01) and 5.1-fold more
[
3H]gemcitabine into DNA than SW1573 cells, respectively. When
corrected for inhibition of RNA synthesis 1mM [
3H]gemcitabine
incorporation into RNA was about 100-fold lower in 2R160
compared to SW1573 and 2R120 cells (data not shown).
Incorporation of gemcitabine may cause DNA damage, which is
the result of the extent of its incorporation and efficacy of the DNA
repair mechanisms. In SW1573 and 2R120 cells, the amount of
dsDNA breaks was concentration dependent (7 and 9% dsDNA
breaks at 0.1mM, 16 and 39% ds breaks at 1mM gemcitabine,
respectively). However, in 2R160 comparable DNA damage was
found at 0.1 and 1.0mM gemcitabine (19 and 25% dsDNA breaks,
respectively).
DISCUSSION
In this paper, we describe an increased collateral sensitivity to
gemcitabine in five pairs of cell lines with an MDR phenotype.
Collateral sensitivity is defined as an increased sensitivity to one
class of drugs, while made resistant to another class of drugs. This
increased sensitivity was associated with an increase in the activity
of dCK in the variant cell lines. Apparently, the increased dCK
activity was related to an upregulation of the gene, reflected by an
increased mRNA and protein content of the cells. Moreover, the
increased dCK activity was stable for many passages, indicating the
structural nature of the upregulation of the gene. Deoxycytidine
kinase plays a pivotal role in gemcitabine activation since it
catalyses the first step in phosphorylation, which is rate limiting
for further phosphorylation to active metabolites. This is based on
the observation that dCK deficiency is associated with gemcitabine
resistance (Bergman et al, 1999, 2000) which can be reverted by
transfection with human dCK (Van der Wilt et al, 2000). The
increased dCK activity is the most logical explanation for the
collateral sensitivity in MDR cells, while the decreased dCDA
activity may add to enhanced intracellular gemcitabine levels
available for phosphorylation. However, the role of dCDA activity
in gemcitabine sensitivity is still not clear (Bergman et al, 2002). The
levels of both dCK mRNA and protein were also higher in 2R120 and
2R160 cells. Comparable differences in dCK levels have been
associated previously with differences in gemcitabine sensitivity
(Kroep et al, 2002). The increase in the activating enzyme was not
only associated with increased retention of dFdCTP pools, but also
with more gemcitabine incorporation into DNA.
Jensen et al (1997) previously described that daunorubicin- and
VM-26-resistant MDR variants of human SCLC cell lines were also
more sensitive to gemcitabine and to the structurally and
functionally related deoxycytidine analogue ara-C. However, the
extent of collateral sensitivity to gemcitabine and ara-C in the
SCLC cell lines was less than that for the present cell lines,
although in the SCLC line also an increased dCK activity was
present (Bergman et al, 2001a). In addition to these cell lines, an
increase in ara-C sensitivity was found in refractory AML cells
displaying a P-gP or MRP overexpression after treatment with
MDR drugs (Schuurhuis et al, 1995). It was suggested that
exposure of cells to an MDR drug might select for a subpopulation
of P-gP- or MRP-overexpressing cells with the more favourable
enzymatic profile for cell survival. Our in vitro data suggest that
the selection process may involve an increase in dCK.
In addition to the structural increase in dCK, Sasva ´ri-Sze ´kely
et al (1998) reported that in human lymphocytes, inhibition of
DNA synthesis by 2-chloro-20deoxyadenosine (Cl-Ado) resulted in
a rapid, transient rise of dCK activity, which was however, not
associated with an increase in the amount of dCK, while dCK
mRNA levels even decreased. Apparently, dCK itself was activated,
probably through a post-translation modification. Moreover, since
dCK is a major enzyme in the supply of essential deoxynucleotides
via the salvage pathway for DNA repair, its activation might be
part of the cellular restoration process occurring after drug
treatment. Unlike the transient increase in dCK activity in human
lymphocytes during Cl-Ado exposure, the increase in dCK activity
found in our NSCLC cell lines seemed to be stable. In 2R120 and
SW1573 cells, 40% of the dCyd phosphorylation was the result of
TK2 activity, while in 2R160 the TK2 activity was two-fold lower.
Since TK2 only phosphorylates small 20-substituted dCyd analo-
gues and ara-C and gemcitabine are poor substrates (Wang et al,
1999), its role in the phosphorylation of gemcitabine might be
limited, although its real contribution has not yet been established.
A reduced TK2 activity might result in a higher dFdCTP/dCTP
ratio in 2R160 cells than in SW1573 cells, which might contribute
to an increased sensitivity to gemcitabine.
The diphosphate of gemcitabine (dFdCDP) inhibits ribonucleo-
tide reductase (RNR), resulting in a decreased conversion of CDP
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Figure 4 Incorporation of [
3H]gemcitabine into DNA relative to
incorporation of [
14C]thymidine (TdR) into DNA (A) and incorporation
of [
3H]gemcitabine into RNA relative to incorporation of [
3H]uridine (UR)
into RNA (B) after 24h exposure to 0.1mM (’) or 1.0mM ( ) gemcitabine
in the human NSCLC cell line SW1573 and its doxorubicin-resistant MDR
cell lines; MRP1-overexpressing 2R120 and P-gP-overexpressing 2R160.
Values are means7s.d. of at least three experiments. *Statistically
significant different from SW1573 cells (t-test, independent samples),
Po0.05, **Po0.02. n.d.¼not detectable.
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sto dCDP and eventually to a depletion of dCTP pools, which can
favour dFdCTP incorporation into DNA (Baker et al, 1991;
Plunkett et al, 1995). The dFdCTP accumulation and retention in
several human tumour cell lines showed a relation with
gemcitabine sensitivity in vitro (Ruiz van Haperen et al, 1994;
Van Moorsel et al, 2000). dFdCTP is not only important as a DNA
precursor, but also interferes with normal ribonucleotide metabo-
lism, such as inhibition of CTP-synthetase and dCMP-deaminase
leading to a depletion of CTP pools and indirectly a decrease of
dCTP pools (Heinemann et al, 1990, 1995; Van Moorsel et al,
1999b, 2000). No difference was found in the retention of dFdCTP
pools of SW1573 cells and its MDR variants after exposure to
1.0mM gemcitabine, which might be related to differences in
nucleoside transport or 50-nucleotidase (5NT) activity, known to
oppose the action of deoxynucleoside kinases (Bergman et al,
2002). However, MDR variants retained dFdCTP pools longer than
SW1573 cells after exposure to 0.1mM gemcitabine. After 24h, no
detectable dFdCTP pools were found in SW1573 cells, which might
be related to the lower dCK activity or altered 5NT activity. The
concentration-dependent [
3H]gemcitabine incorporation into
DNA and correlation of DNA damage with sensitivity is in
agreement with previous studies in ovarian, colon and leukaemia
cell lines (Huang et al, 1991; Ruiz van Haperen et al, 1993b).
However, no relation was found between [
3H]gemcitabine
incorporation into RNA and sensitivity to gemcitabine, leaving a
dubious role for RNA incorporation in gemcitabine toxicity
(Bergman et al, 2002). Most likely, the increased dFdCTP
retention, gemcitabine incorporation and increased sensitivity to
gemcitabine are all downstream events of an increased dCK
activity, underlining the pivotal role of dCK in gemcitabine
sensitivity.
Verapamil is a strong inhibitor of P-gP, but only a partial
inhibitor of MRP activity (Aszalos et al, 1999). A concentration of
10mM verapamil increased sensitivity to doxorubicin of MRP1-
transfected NIH/3T3 mouse fibroblasts, but reversal was incom-
plete (Breuninger et al, 1995). Since we used a 2.5-fold higher
verapamil concentration, MRP1 inhibition might be more effective.
Reversal of collateral sensitivity to gemcitabine was found both in
P-gP- and MRP1-overexpressing cells. We did not find a direct
correlation between the extent of P-gP and MRP1 activity and
sensitivity to gemcitabine or dCK activity. Apparently, a certain
threshold level of P-gP or MRP1 activity is required for an increase
in gemcitabine sensitivity, in contrast to the resistance to, for
example, doxorubicin. The observation that verapamil reverted the
collateral sensitivity of the MDR cells to gemcitabine suggests a
possible relation between the presence of a certain membrane
efflux pump activity, gemcitabine sensitivity and a transient
regulation of dCK activity. One of these mechanisms may include
regulation by protein kinase C (PKC) activity. Several studies
report an increase in PKC activity in cells with an overexpression
of P-gP or MRP (Beck et al, 1998; Ratnasinghe et al, 1998). P-
glycoprotein and MRP are phosphorylated (Ma et al, 1995; Clavy
et al, 1997); however, it is a matter of debate whether phosphoryla-
tion modulates the pump function (Ma et al, 1995; Smith and
Zilfou, 1995; Clavy et al, 1997; Ratnasinghe et al, 1998). Since dCK
may be phosphorylated by PKC, and exhibits a higher activity
in the phosphorylated state (Wang and Kucera, 1994), PKC
might play a role in the collateral sensitivity to gemcitabine of
MDR cells.
Since P-gP and MRP act as an efflux pump for steroid
hormones, such as cortisol, progesterone and aldosterone (Van
Kalken et al, 1993; Mulder et al, 1996) and several studies reported
a decrease in TK activity as a result of steroid hormone exposure in
chicken embryo retina (Naray et al, 1977; Herzfield and Raper,
1980; Tesoriere et al, 1989), verapamil might inhibit the efflux of
these compounds, leading to a transient downregulation of dCK.
Clinically relevant concentrations of the steroid drug dexametha-
sone inhibited the effect of gemcitabine in cultured human glioma
cells (Rieger et al, 1999). Moreover, dexamethasone decreased
gemcitabine sensitivity of 2R120 and 2R160 cells, and decreased
dCK activity in 2R160 cells, but only in the presence of verapamil
(Bergman et al, 2001b).
In conclusion, MRP1- and P-gP-overexpressing cells were more
sensitive to gemcitabine than their parental cells. This increased
sensitivity was related to dCK and gemcitabine effects on DNA.
Since relapsed tumours of patients after treatment with MDR drugs
frequently display an MDR phenotype, screening for a P-gP or
MRP1 overexpression, as a predictor of gemcitabine responsive-
ness, might be of clinical interest.
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